First Time Loading...

Chengdu Kanghong Pharmaceutical Group Co Ltd
SZSE:002773

Watchlist Manager
Chengdu Kanghong Pharmaceutical Group Co Ltd Logo
Chengdu Kanghong Pharmaceutical Group Co Ltd
SZSE:002773
Watchlist
Price: 22.48 CNY -1.27% Market Closed
Updated: May 23, 2024
Section:
 

Relative Value

The Relative Value of one Chengdu Kanghong Pharmaceutical Group Co Ltd stock under the Base Case scenario is 18.1 CNY. Compared to the current market price of 22.48 CNY, Chengdu Kanghong Pharmaceutical Group Co Ltd is Overvalued by 20%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
18.1 CNY
Overvaluation 20%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5
P/S
P/S
Price to Sales
5
vs History
49
vs Industry
26
Median 3Y
4.4
Median 5Y
5
Industry
2.5
Forward
4.9
More Details
18.1
P/E
P/E
Price to Earnings
18.1
vs History
61
vs Industry
27
Median 3Y
17.9
Median 5Y
25
Industry
23.5
Forward
17.2
More Details
14.4
P/OCF
P/OCF
Price to OCF
14.4
vs History
85
vs Industry
29
Median 3Y
18.1
Median 5Y
39
Industry
17.4
More Details
15.9
P/FCFE
P/FCFE
Price to FCFE
15.9
vs History
46
vs Industry
26
Median 3Y
17.1
Median 5Y
15.4
Industry
24.3
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
50
vs Industry
30
Median 3Y
2.4
Median 5Y
2.7
Industry
2.1
More Details
3.8
EV/S
EV/S
Enterprise Value to Sales
3.8
vs History
49
vs Industry
32
Median 3Y
3.6
Median 5Y
3.9
Industry
2.6
Forward
3.8
More Details
4.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.4
vs History
50
vs Industry
47
Median 3Y
4
Median 5Y
4.5
Industry
5.3
More Details
12.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.6
vs History
61
vs Industry
29
Median 3Y
12.2
Median 5Y
22.6
Industry
13.7
Forward
10.3
More Details
12.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.6
vs History
61
vs Industry
33
Median 3Y
12.2
Median 5Y
22.6
Industry
17.4
Forward
11.2
More Details
11.1
EV/OCF
EV/OCF
Enterprise Value to OCF
11.1
vs History
84
vs Industry
35
Median 3Y
14.4
Median 5Y
36
Industry
16.2
More Details
12.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
12.3
vs History
30
vs Industry
27
Median 3Y
12.3
Median 5Y
-99.1
Industry
18.6
More Details
4.6
EV/IC
EV/IC
Enterprise Value to IC
4.6
vs History
42
vs Industry
19
Median 3Y
3.5
Median 5Y
4.1
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Chengdu Kanghong Pharmaceutical Group Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Chengdu Kanghong Pharmaceutical Group Co Ltd
SZSE:002773
20.7B CNY 5 18.1 12.6 12.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
771.7B USD 21.5 125.8 61.5 69.9
DK
Novo Nordisk A/S
CSE:NOVO B
4.2T DKK 17.1 46.7 34.8 38.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
365.4B USD 4.3 9.5 11.7 15.3
US
Merck & Co Inc
NYSE:MRK
333.6B USD 5.4 144.7 36 58.8
UK
AstraZeneca PLC
LSE:AZN
192.7B GBP 5.1 38.7 175 279.2
CH
Roche Holding AG
SIX:ROG
185.7B CHF 3.2 16.2 9.2 10.9
CH
Novartis AG
SIX:NOVN
181.7B CHF 3.4 11.3 8.6 12.6
US
Pfizer Inc
NYSE:PFE
164.2B USD 3 -530.4 12.9 20.8
P/E Multiple
Earnings Growth
CN
Chengdu Kanghong Pharmaceutical Group Co Ltd
SZSE:002773
Average P/E: 51.4
18.1
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
125.8
346%
DK
Novo Nordisk A/S
CSE:NOVO B
46.7
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.5
-21%
US
Merck & Co Inc
NYSE:MRK
144.7
7 453%
UK
AstraZeneca PLC
LSE:AZN
38.7
168%
CH
Roche Holding AG
SIX:ROG
16.2
26%
CH
Novartis AG
SIX:NOVN
11.3
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -530.4
680%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 140,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.